Apical Ischemia Is a Universal Feature of Apical Hypertrophic Cardiomyopathy
Rebecca K. HughesJoão B. AugustoKristopher KnottRhodri DaviesHunain ShiwaniAndreas SeraphimJames W. MalcolmsonShafik KhouryGeorge JoySaidi MohiddinLuis R. LopesWilliam J. McKennaPeter KellmanHui XueMaite TomeSanjay SharmaGabriella CapturJames C. MoonInstitute of Cardiovascular Science (R.K.H.,J.B.A.,K.K.,R.D.,H.S.,A.S.,G.J.,L.R.L.,W.J.M.,G.C.,J.C.M.),University College London,United Kingdom.MRC Unit for Lifelong Health and Ageing (R.D.,G.C.),University College London,United Kingdom.Barts Heart Centre,The Cardiovascular Magnetic Resonance Imaging Unit and The Inherited Cardiovascular Diseases Unit,St Bartholomew's Hospital,West Smithfield,London,United Kingdom (R.K.H.,J.B.A.,K.K.,R.D.,H.S.,A.S.,J.W.M.,G.J.,S.M.,L.R.L.,J.C.M.).Cardiology Department,Hospital Professor Doutor Fernando Fonseca,Amadora,Portugal (J.B.A.).William Harvey Institute,Queen Mary University of London,United Kingdom (J.W.M.,S.M.,M.T.,S.S.).Cardiovascular Clinical and Academic Group,Molecular and Clinical Sciences Institute,St. George's University of London,United Kingdom (S.K.)Instituto de Investigación Biomédica de A Coruña,Spain (W.J.M.).National Heart,Lung,and Blood Institute,National Institutes of Health,Department of Human and Health Services,Bethesda,MD (P.K.,H.X.).Department of Cardiology,Inherited Heart Muscle Conditions Clinic,Royal Free Hospital,NHS Trust,United Kingdom (G.C.).
DOI: https://doi.org/10.1161/CIRCIMAGING.122.014907
2023-03-22
Abstract:Circulation: Cardiovascular Imaging, Volume 16, Issue 3, Page e014907, March 1, 2023. Background:Apical hypertrophic cardiomyopathy (ApHCM) accounts for ≈10% of hypertrophic cardiomyopathy cases and is characterized by apical hypertrophy, apical cavity obliteration, and tall ECG R waves with ischemic-looking deep T-wave inversion. These may be present even with <15 mm apical hypertrophy (relative ApHCM). Microvascular dysfunction is well described in hypertrophic cardiomyopathy. We hypothesized that apical perfusion defects would be common in ApHCM.Methods:A 2-center study using cardiovascular magnetic resonance short- and long-axis quantitative adenosine vasodilator stress perfusion mapping. One hundred patients with ApHCM (68 overt hypertrophy [≥15 mm] and 32 relative ApHCM) were compared with 50 patients with asymmetrical septal hypertrophy hypertrophic cardiomyopathy and 40 healthy volunteer controls. Perfusion was assessed visually and quantitatively as myocardial blood flow and myocardial perfusion reserve.Results:Apical perfusion defects were present in all overt ApHCM patients (100%), all relative ApHCM patients (100%), 36% of asymmetrical septal hypertrophy hypertrophic cardiomyopathy, and 0% of healthy volunteers (P<0.001). In 10% of patients with ApHCM, perfusion defects were sufficiently apical that conventional short-axis views missed them. In 29%, stress myocardial blood flow fell below rest values. Stress myocardial blood flow was most impaired subendocardially, with greater hypertrophy or scar, and with apical aneurysms. Impaired apical myocardial blood flow was most strongly predicted by thicker apical segments (β-coefficient, −0.031 mL/g per min [CI, −0.06 to −0.01];P=0.013), higher ejection fraction (−0.025 mL/g per min [CI, −0.04 to −0.01];P<0.005), and ECG maximum R-wave height (−0.023 mL/g per min [CI, −0.04 to −0.01];P<0.005).Conclusions:Apical perfusion defects are universally present in ApHCM at all stages. Its ubiquitous presence along with characteristic ECG suggests ischemia may play a disease-defining role in ApHCM.
radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems